KGF Human
(a) Analysis by RP-HPLC.
(b) Analysis by SDS-PAGE.
Description
The FGF-7 is purified by proprietary chromatographic techniques.
Product Specs
Product Science Overview
Keratinocyte Growth Factor (KGF), also known as Fibroblast Growth Factor 7 (FGF7), is a potent mitogen specifically for epithelial cells. It plays a crucial role in the proliferation, differentiation, and migration of these cells, as well as in protecting them from various insults under stress conditions . The recombinant form of KGF, known as human recombinant KGF (rhKGF), has been developed for therapeutic purposes.
KGF was originally isolated from human embryonic lung fibroblast-conditioned medium. It belongs to the fibroblast growth factor (FGF) family, which comprises 23 members classified into six subfamilies in mammals . The original KGF-1 cDNA, encoding 194 residues, was isolated from a human embryonic lung fibroblast cell line. It contains 31 residues of signal peptide and five N- and O-glycosylation sites .
The production of recombinant human KGF involves expressing the protein in a suitable host, such as Escherichia coli. In one study, an amino-terminally truncated KGF-1 variant with 135 residues was produced and purified in E. coli. This variant demonstrated biological activity similar to the full-length KGF-1 . The recombinant form, known as palifermin (trade name Kepivance®), is used to prevent and treat oral mucositis following radiation or chemotherapy .
KGF interacts with the FGF receptor 2 (FGFR2-IIIb), which is specifically expressed in stromal fibroblasts from epithelial tissues . This interaction promotes the growth of epithelial cells and plays an important role in repairing the epithelium in various tissues and organs during the early stages of wound healing . Additionally, KGF has been shown to stimulate the growth of hair follicles and repress hair growth during the telogen phase .
Recombinant human KGF has been developed for several therapeutic applications. One of the most notable uses is in the treatment of oral mucositis, a common side effect of radiation and chemotherapy. Palifermin has been shown to reduce the incidence and duration of severe oral mucositis in patients undergoing these treatments . Additionally, KGF has been investigated for its potential in treating other conditions, such as hemorrhagic cystitis, where it has shown promising results in promoting the proliferation of urothelial cells and reducing bleeding .
